

## Coagulation Assays

Nigel S. Key, MB ChB FRCP  
Harold R. Roberts Distinguished Professor  
Director, UNC Hemophilia and Thrombosis Center



THE UNIVERSITY  
of NORTH CAROLINA  
at CHAPEL HILL

ISTH Bangkok  
November, 2017




## Disclosures

Research Support/P.I.	NIH/NHLBI; Doris Duke Foundation; Baxalta/Shire
Employee	No relevant conflicts of interest to declare
Consultant	CSL Behring; Baxalta/Shire; Genentech/Roche; Novo Nordisk
Major Stockholder	No relevant conflicts of interest to declare
Speakers Bureau	No relevant conflicts of interest to declare
Honoraria	No relevant conflicts of interest to declare
Scientific Advisory Board	RTI International

Presentation includes discussion of the following off-label use of a drug or medical device:  
None


## Overview

- The Basics
  - The TT (TCT)
  - The PT
  - The aPTT
  - The Mixing Study
  - One-stage and chromogenic factor assays
- Global Assays
  - PFA-100
  - TEG/ROTEM
  - Thrombin generation




## Screening Tests of Coagulation

- Blood is anticoagulated in a calcium sequestering agent (citrate)
- Plasma is separated by centrifugation
- Coagulation is initiated by adding an activating agent (usually with calcium and phospholipid)
- Time to clot formation is measured in seconds
- Routine coagulation tests:
  - Prothrombin Time (PT)
  - Activated Partial Thromboplastin Time (aPTT)
  - Thrombin Time (TT) [= Thrombin clotting time (TCT)]




## THE THROMBIN TIME (TT) OR (TCT)

### What is measured in the thrombin time?



## Performing a Thrombin Time

Note:  $\text{Ca}^{++}$ , Phospholipid  
**NOT** required



## What Causes a Prolonged TT?


1. **Low fibrinogen** ( 'hypofibrinogenemia' )
2. **Abnormal fibrinogen** ( 'dysfibrinogenemia' )
  - inherited
  - acquired (severe liver disease)
3. **Inhibitor of added thrombin**
  - direct inhibitor; e.g. **argatroban**, **dabigatran**
  - indirect inhibitor; **heparin**
4. **Something that interferes with fibrin polymerization**
  - paraproteinemia
  - very high levels of fibrin degradation products
  - very high level of fibrinogen

## THE PROTHROMBIN TIME (PT)

## Performing the Prothrombin Time




Armand  
Quick 1935



## The Prothrombin Time (PT)


Thromboplastin (reagent) provides tissue factor (TF) and phospholipid (PL)



## What Causes a Prolonged PT?

- Anything that prolongs the TT
  - but the PT is *much* less sensitive than the TT to the presence of heparin, abnormal fibrinogen, and FDPs
- Anything that lowers levels or inhibits the common pathway factors
  - Factor X
  - Factor V
  - Factor II (prothrombin)
  - Fibrinogen
- And also low levels of FVII
  - Congenital
  - Acquired
    - Deficiency of Vitamin K
    - Vitamin K inhibitors
    - DIC
    - Liver disease

## PT Performed with Dilute Thromboplastin Can Detect Hemophilia




## Relationship Between PT and INR

- INR = International Standardized ratio
- Developed as a reporting tool to allow PT measurements from different laboratories to be comparable.
- The ratio of the patient's PT divided by the mean normal PT—raised to an exponent called the ISI (which is dependent on the thromboplastin source)
  - The ISI is calculated for each new batch of thromboplastin.
- Normal value for INR is  $\approx 1$ .
- Technically, INR was developed to be used exclusively for monitoring warfarin, but other scoring systems have since incorporated the INR (e.g. Child-Pugh cirrhosis score)


## THE ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)

### 1953: Invention of the (a)PTT



Drs. Langdell, Wagner and Brinkhous 1977

### The (activated) Partial Thromboplastin Time (PTT or aPTT)






### Definitions

- The "activator" in the aPTT
  - Provides negative charges to activate the contact system
  - Things that can do this include kaolin, celite, and silica
- What's missing in the "Partial thromboplastin" that's present in a complete thromboplastin?
  - The partial thromboplastin is **missing tissue factor**.
  - It DOES have phospholipid

## What Causes a Prolonged aPTT?

- Problems with factors in the common pathway
  - Factor II, V, X
  - Fibrinogen
- Problems with the contact factors
  - Factor XII, HMWK, PK
- Problems with
  - Factor XI—Hemophilia C
  - Factor IX—Hemophilia B
  - Factor VIII—Hemophilia A
- Warfarin in excess, or severe vitamin K deficiency (due to their effects on IX, X, and II)
- Heparin (unfractionated)
- Lupus Inhibitor (AKA Lupus anticoagulant)




## THE MIXING STUDY

### The Mixing Study


- Helps us differentiate between the two broad causes of a prolonged aPTT
- When there's a prolonged aPTT, the broad differential diagnosis is
  - Factor deficiency (something's missing)
  - Inhibitor (something's interfering)
- Take the patient's plasma and mix it 1:1 with normal plasma—then repeat the aPTT

### Interpreting the Mixing Study



### Factor Assays

- A method based on the PT is used to measure levels of factors V, VII, X and II.
- The assay relies upon correction of the PT when the test plasma is added to plasma deficient in the factor to be measured
- Perform a PT on the mix (at various dilutions)—then figure out where on the reference curve the patient falls—derive the FVIII activity level from the PT



## FVIII Bioassays


### 1- stage assay

- Clot based
- Shorter incubation time (<2 min)
- Sensitive to pre-activation of FVIII
- Based on aPTT
- Need FVIII-deficient reagent plasma with surplus of other clotting factors
- Easy to automate
- High CV (up to 40%), especially at lower FVIII levels

### 2 – stage assay


- Clot based
- Longer incubation time (up to 12 min)
- Does not require FVIII-deficient plasma
- Not sensitive to pre-activation of FVIII
- Difficult to automate
- Lower CV

## Overview of 1-Stage and 2-Stage FVIII Assays



## Chromogenic FVIII Assay: A Reasonable Compromise?

- Reference method recommended by the ISTH to measure FVIII activity in plasma and FVIII concentrates
- Not clot based
- Does not require FVIII-deficient plasma
- High dilution of patient sample minimizes interferences
- Low CV (2.4-7.4%)
- Can be easily automated






### “Non-Linear Assay: Inhibitory Pattern”


Dilution	FVIII	FIX
1:5	*	1.8
1:10	*	18.2
1:20	*	50.7
1:40	*	69.3
1:80	*	70.6

- Serial dilutions are performed, and the assays are corrected for the dilution factor.
- An apparent rise in the factor activity level with deeper and deeper dilutions is indicative of the presence of a non-specific inhibitor affecting the aPTT.
- If there is a specific inhibitor to that particular factor, then the activity level is low and remains low.
- In this example, there is a FVIII inhibitor that is interfering with the aPTT-based FIX assay. This would be reported as FIX >70.6%--inhibitory pattern noted.


### The Bethesda Assay



### PFA-100™ Test Principle



### PFA-100™ Simulates Primary Hemostasis



### PFA-100™ Closure Times: Interpretation


	C-Epi Normal	C-Epi ↑
<b>C-ADP</b> <b>Normal</b>	Excludes: Drug effect Severe thrombocytopenia severe platelet dysfunction Severe VWD	Drug effect (ASA, NSAID) Low Hct Mild thrombocytopenia Mild platelet dysfunction Mild VWD
<b>C-ADP ↑</b>	Rare event	Drug effect Very low Hct Severe thrombocytopenia Severe platelet dysfunction Severe VWD

### Viscoelastic Hemostasis Assays


TEG




ROTEM



### TEG Parameters




## TEG Phases Related to Hemostatic Processes




## Assays Used in Rotational Thromboelastometry (ROTEM)


Assay	Activator/Inhibitor	Information Provided
INTEM	Contact activation	Fast assessment of clot formation, fibrin polymerization, and fibrinolysis via the intrinsic pathway
HEPTEM	Contact activation + heparinase	ROTEM analysis without heparin influence: Specific detection of heparin (compared to INTEM), assessment of clot formation in heparinized patients
EXTEM	Tissue factor activation	Fast assessment of clot formation, fibrin polymerization, and fibrinolysis via the extrinsic pathway
FIBTEM	Tissue factor activation + platelet inhibition	ROTEM analysis without platelets: Qualitative assessment of fibrinogen status
APTEM	Tissue factor activation + aprotinin	In vitro fibrinolysis inhibition: Fast detection of lysis when compared with EXTEM
NATEM	Recalcification only = classical TEM (thromboelastometry)	Very sensitive assessment of the equilibrium of coagulation activation or inhibition



## Thrombin Generation Curve Using Calibrated Automated Thrombography (CAT) Assay (Platelet-Free Plasma)



Assay triggered by low concentration TF (1 pM) with added phospholipid (4 μM)



Thromboscope™